Paid Colon Cancer Clinical Trials
Colorectal cancer clinical trials actively recruiting. Access immunotherapy and targeted treatments. Compensation for patients with advanced CRC.
Compensation
$1,500 - $4,500
Duration
24-104 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18 years or older
- Histologically confirmed colorectal adenocarcinoma
- Known tumor molecular status (MSI, RAS, BRAF)
- Measurable disease per RECIST criteria
- ECOG performance status 0-1
- Adequate hematologic and organ function
Who May Not Qualify
- Symptomatic brain metastases
- Complete bowel obstruction
- Active bleeding or high bleeding risk
- Prior severe reaction to study drug class
- Uncontrolled ascites
Frequently Asked Questions
What colorectal cancer treatments are being studied?
+
Studies include checkpoint inhibitors (especially for MSI-high tumors), targeted therapies for specific mutations, antibody-drug conjugates, and novel combination regimens.
Do I need to know my tumor mutation status?
+
Yes, molecular profiling (MSI status, RAS, BRAF mutations) is typically required and guides treatment selection. Testing is often provided during screening.
How often are imaging scans performed?
+
CT scans are typically performed every 8-12 weeks to assess treatment response. Additional imaging may be performed for symptom evaluation.
Are there studies for patients who have already received chemotherapy?
+
Yes, many studies are designed for patients whose cancer has progressed after standard chemotherapy regimens. The number of prior therapies required varies by study.